Article
Oncology
Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice Andre, Attila Tordai, Jaime A. Mejia, W. Fraser Symmans, Ana M. Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobagyi, Lajos Pusztai
Summary: This study compared the response to neoadjuvant chemotherapy and survival between patients with triple-negative breast cancer (TNBC) and non-TNBC. The results showed that TNBC patients had higher pathologic complete response rates but lower 3-year progression-free survival rates and 3-year overall survival rates. TNBC was associated with increased risk for visceral metastases, lower risk for bone recurrence, and shorter postrecurrence survival. Patients with TNBC had worse survival if they had residual disease after neoadjuvant chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Michal Budzik, Maciej Sobieraj, Maria Sobol, Janusz Patera, Aleksandra Czerw, Andrzej Deptala, Anna Badowska-Kozakiewicz
Summary: Medullary breast cancer (MdBC) is a rare and highly malignant type of breast cancer. MdBC patients tend to be younger, have higher histological grade, larger tumor size, and less frequent lymph node involvement. Most MdBCs are triple-negative (not expressing estrogen receptor, progesterone receptor, and HER2 receptor), while IDCs are predominantly luminal (expressing estrogen receptor and/or progesterone receptor).
ARCHIVES OF MEDICAL SCIENCE
(2022)
Article
Oncology
Michal Marczyk, Tao Qing, Tess O'Meara, Vesal Yagahoobi, Vasiliki Pelekanou, Yalai Bai, Emily Reisenbichler, Kimberly S. Cole, Xiaotong Li, Vignesh Gunasekharan, Eiman Ibrahim, Kristina Fanucci, Wei Wei, David L. Rimm, Lajos Pusztai, Kim R. M. Blenman
Summary: Differences in the tumor immune microenvironment may exist between African American and NonAA breast cancer patients, which may impact treatment response and prognosis.
Article
Health Care Sciences & Services
Taobo Hu, Yan Chen, Yiqiang Liu, Danhua Zhang, Jiankang Pan, Mengping Long
Summary: The loss of PR expression in ER+/HER2- breast cancers indicates a worse prognosis and insensitivity to anti-estrogen therapy. Various PR expression statuses in these cancers can be indicative of molecular variation, particularly in relation to the activation of growth factor pathways.
BMC MEDICAL RESEARCH METHODOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Stuti Roy, Suryendu Saha, Debanil Dhar, Puja Chakraborty, Kumar Singha Roy, Chitranjan Mukherjee, Arnab Gupta, Samir Bhattacharyya, Anup Roy, Sanghamitra Sengupta, Susanta Roychoudhury, Somsubhra Nath
Summary: This study reveals the role of CUEDC2 in breast cancer, especially in endocrine resistance and mitotic progression. Upregulation of CUEDC2 renders ERα+ve tumors behave similarly to HR-ve tumors with an increase in aneuploidy. Furthermore, CUEDC2 is identified as a potential prognostic marker and therapeutic target in breast cancer management.
CANCER GENE THERAPY
(2022)
Article
Oncology
Iris Noordhoek, Kai Treuner, Hein Putter, Yi Zhang, Jenna Wong, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Cornelis J. H. van de Velde, Catherine A. Schnabel, Gerrit-Jan Liefers
Summary: This study found that BCI (H/I) as a biomarker could predict the benefit of extended endocrine therapy in patients with early-stage HR+ breast cancer, providing important clinical implications for treatment decisions.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Francoise Beltjens, Damien Molly, Aurelie Bertaut, Corentin Richard, Isabelle Desmoulins, Catherine Loustalot, Celine Charon-Barra, Emilie Courcet, Anthony Bergeron, Sylvain Ladoire, Clementine Jankowski, Romain Boidot, Laurent Arnould
Summary: The study confirmed that ER-/PR+ breast cancers are an extremely rare but real subtype, morphologically and histologically similar to triple-negative tumors, with more aggressive phenotypes and differing responses to therapies and clinical outcomes. The likely involvement of SUZ12 in their biology offers potential for the development of new therapeutic alternatives.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
E. S. Grigoryeva, L. A. Tashireva, V. V. Alifanov, O. E. Savelieva, S. V. Vtorushin, M. V. Zavyalova, O. D. Bragina, E. Y. Garbukov, N. V. Cherdyntseva, E. L. Choinzonov, V. M. Perelmuter
Summary: Molecular subtype conversion in circulating tumor cells could be a promising tool for optimizing antitumor therapy in breast cancer patients.
SCIENTIFIC REPORTS
(2022)
Article
Multidisciplinary Sciences
Depeng Wang, Wei Xu, Minghua Huang, Wei Ma, Yulu Liu, Xingchen Zhou, Qingrui Yang, Kun Mu
Summary: Drug resistance is common in triple-negative breast cancer (TNBC) and leads to poor prognosis. Targeting the DNA damage response (DDR) has shown to be effective in overcoming chemotherapy resistance in TNBC. CENPF, a key regulator of cell cycle progression, is highly expressed in TNBC and is associated with chemotherapy resistance. Knockdown of CENPF increases cytotoxicity in TNBC cells and overcomes adriamycin resistance. CENPF targets the Chk1-mediated G2/M phase arrest and competes with E2F1 in TNBC, providing a novel mechanism to overcome chemotherapy resistance.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Summary: Resistance to endocrine treatment in ER+ breast cancer patients is linked to activation of HER2 due to loss of mismatch repair, and inhibiting HER2 restores sensitivity to treatment. Loss of MutL and upregulation of HER2 are associated with sensitivity to HER inhibitors in ER+/HER2(-) patients.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Fei Fei, Gene P. Siegal, Shi Wei
Summary: The study analyzed clinicopathologic features and clinical outcomes of ER-low-positive breast cancers. ER-low-positive tumors showed significantly better prognosis compared to ER-negative tumors, with overlapping survival outcomes with ER-positive tumors in the entire cohort.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Andrea Ronchi, Francesca Pagliuca, Federica Zito Marino, Marina Accardo, Immacolata Cozzolino, Renato Franco
Summary: Biomarkers on cancer tissue samples can be identified through technologies like immunohistochemistry and in situ hybridization, especially in breast cancer pathology for diagnostic, prognostic, and therapeutic response purposes. Pathologists play an increasingly important role in defining prognosis and choosing therapy based on immunohistochemical biomarkers, guiding treatment and classifying breast cancer into distinct subtypes.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Hengqiang Zhao, Yiping Gong
Summary: Single estrogen receptor (ER)+ and progesterone receptor (PR)+ tumors account for about 10% of all breast cancers. The prognosis of these tumors varies based on HER2 status, with single ER+ and PR+ patients showing different survival outcomes in different HER2 subtypes. In HER2- subtype, single PR+ patients had poorer prognoses than single ER+ patients, while in HER2+ subtype, single ER+ and PR+ patients showed similar prognoses compared with ER-PR- patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Danian Dai, Hongmei Wu, Hongkai Zhuang, Rong Chen, Cheng Long, Bo Chen
Summary: This study investigated the clinical and genetic characteristics of ER + / PR- breast cancer patients in China. Different PR statuses indicated diverse biological processes of ER + breast cancer and survival outcomes. Tailored treatment strategies may be needed for ER + / PR- patients.
Article
Pathology
Di Ai, Jun Yao, Fei Yang, Lei Huo, Hui Chen, Wei Lu, Luisa Maren Solis Soto, Mei Jiang, Maria Gabriela Raso, Shufang Wang, Diana Bell, Jinsong Liu, Huamin Wang, Dongfeng Tan, Carlos Torres-Cabala, Qiong Gan, Yun Wu, Constance Albarracin, Mien-Chie Hung, Funda Meric-Bernstam, Ignacio I. Wistuba, Victor G. Prieto, Aysegul A. Sahin, Qingqing Ding
Summary: Currently, there is no highly specific and sensitive marker for breast cancer, leading researchers to investigate TRPS1 as a potential marker. The study found that TRPS1 is highly expressed in all subtypes of breast carcinoma and may serve as a valuable diagnostic tool, particularly for TNBC. Additionally, TRPS1 showed little to no expression in other solid tumor types, highlighting its potential specificity for breast carcinoma.